Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771638 · ClinicalTrials.gov registry record · Phase 4
DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men
A Phase 4 study, sponsored by Public Health Foundation Enterprises.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT03771638 is a Phase 4 study that has completed, run by Public Health Foundation Enterprises. The registered enrollment target is 100 participants.
The verdict
NCT03771638, a Phase 4 study, has completed, sponsored by Public Health Foundation Enterprises.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill was swallowed. The goal of this study is to assess the impact of the app on adherence to HIV pre-exposure prophylaxis (PrEP) for the prevention of HIV.
Interventions
- DRUG Emtricitabine / Tenofovir Disoproxil Oral Tablet
- OTHER DOT Diary mobile app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2020-04-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03771638
The ClinicalTrials.gov registry entry for NCT03771638 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Public Health Foundation Enterprises, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Emtricitabine / Tenofovir Disoproxil Oral Tablet is the first listed.
NCT03771638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03771638 about?
NCT03771638 is a clinical study titled "DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men". The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill wa...
What is the current status of trial NCT03771638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2019-02-01. Estimated completion is 2020-04-21.
What interventions are being tested in trial NCT03771638?
The interventions under investigation include: Emtricitabine / Tenofovir Disoproxil Oral Tablet (DRUG), DOT Diary mobile app (OTHER).
Who is sponsoring clinical trial NCT03771638?
This trial is sponsored by Public Health Foundation Enterprises, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.